FTRE
Fortrea Holdings Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.42
−0.31%Oct 19, 2026, 20:05 UTC
Fortrea Holdings Inc. completed its acquisition of the Early Phase Services division from Worldwide Clinical Trials LLC.
Source:Oct 5, 2026, 10:30 UTC
Fortrea announced it will release its third quarter 2026 financial results before market open on October 29, 2026, and host a conference call that day at 8:00 a.m. ET.
Source:Sep 30, 2026, 20:14 UTC
Fortrea Holdings Inc. appointed Carrie Russell as Chief Accounting Officer, effective October 5, 2026, with a base salary of $340,000 and a 40% bonus target.
Sep 10, 2026, 21:08 UTC
Fortrea granted inducement awards of restricted stock units and performance share units to five newly hired employees on September 10, 2026.
Source:Sep 10, 2026, 11:02 UTC
Fortrea Holdings Inc. appointed Jason Knoblauch as Chief Financial Officer effective September 9, 2026, with David Smith serving as Interim Chief Financial Officer.
Sep 2, 2026, 11:00 UTC
Fortrea agreed to acquire the clinical pharmacology unit and bioanalytical laboratory operations from Worldwide Clinical Trials, adding dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network.
Jul 29, 2026, 10:30 UTC
Fortrea reports its second quarter 2026 financial results and raises full-year guidance.
Jul 29, 2026, 00:00 UTC
Fortrea Holdings Inc. appointed David Smith as Interim Chief Financial Officer and principal financial officer, effective July 27, 2026.
Jun 26, 2026, 11:00 UTC
Fortrea appointed Jason Knoblauch as its new Chief Financial Officer, succeeding Jill McConnell.
Source: